Related Experiment Videos
Efficacy of NY-198 against experimental Legionnaires disease
S Kohno1, K Yamaguchi, Y Dohtsu
1Second Department of Internal Medicine, School of Medicine, Nagasaki University, Japan.
Abstract:
The in vitro and in vivo effects of NY-198 against Legionella pneumophila were compared with those of ciprofloxacin. The MIC of NY-198 against 15 standard reference strains of Legionella of various species, between 0.03 and 0.125 micrograms/ml, was the same as that of ciprofloxacin. The peak concentration of NY-198 in the lungs and sera of guinea pigs with experimentally induced Legionella pneumonia was higher than that of ciprofloxacin after oral administration. The overall survival rate was higher in animals treated with NY-198 than in those treated with ciprofloxacin. Thus, NY-198 appears valuable in the treatment of Legionnaires disease.
Insights
NY-198 demonstrates potent efficacy against Legionella pneumophila, matching ciprofloxacin in vitro. In vivo studies showed NY-198 achieved higher lung concentrations and improved survival rates in treating Legionnaires disease.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Legionella pneumophila is a significant cause of bacterial pneumonia.
- Developing effective treatments for Legionnaires disease remains critical.
Purpose of the Study:
- To evaluate the in vitro and in vivo efficacy of NY-198 against Legionella pneumophila.
- To compare NY-198 with ciprofloxacin, a standard treatment, for Legionnaires disease.
Main Methods:
- In vitro antimicrobial susceptibility testing (MIC) against 15 Legionella reference strains.
- In vivo pharmacokinetic study in guinea pigs with experimentally induced Legionella pneumonia.
- Comparison of survival rates in animal models treated with NY-198 versus ciprofloxacin.
Main Results:
- NY-198 exhibited equivalent Minimum Inhibitory Concentrations (MICs) to ciprofloxacin against Legionella species (0.03–0.125 µg/ml).
- Oral administration of NY-198 resulted in higher peak concentrations in lung tissue and serum compared to ciprofloxacin.
- Animals treated with NY-198 showed a significantly higher overall survival rate.
Conclusions:
- NY-198 possesses strong in vitro activity against Legionella.
- NY-198 demonstrates superior in vivo pharmacokinetic properties and survival benefit in a model of Legionnaires disease.
- NY-198 shows promise as a valuable therapeutic agent for treating Legionnaires disease.